APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Adeno-Associated Virus (AAV) Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Adeno-Associated Virus (AAV) Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174484650312 August 2026196 pages

Choose your research edition.

Industry ResearchAdeno-Associated Virus (AAV) Gene Therapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Adeno-Associated Virus (AAV) Gene Therapy Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adeno-Associated Virus (AAV) Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Analysis and Forecast 2026-2032186 pages · $4,950 USD

Market perspective

The global Adeno-Associated Virus (AAV) Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Adeno-Associated Virus (AAV) Gene Therapy include AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech and Sarepta Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Adeno-Associated Virus (AAV) Gene Therapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adeno-Associated Virus (AAV) Gene Therapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adeno-Associated Virus (AAV) Gene Therapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Adeno-Associated Virus (AAV) Gene Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Adeno-Associated Virus (AAV) Gene Therapy Segment by Company

AGC Biologics

StrideBio

SIRION Biotech

Neurophth Biotechnology

Belief BioMed

BiBo Biopharma Engineering Co., LTD.

Beihai Kangcheng

PackGene Biotech

Sarepta Therapeutics

Carbon BioSciences

Kelonia Therapeutics

Roche

Remedium Bio

Creative Biolabs

Affinia Therapeutics

Spark Therapeutics

Adeno-Associated Virus (AAV) Gene Therapy Segment by Type

Luxturna

Zolgensma

Others

Adeno-Associated Virus (AAV) Gene Therapy Segment by Application

Central Nervous System Diseases

Ocular Diseases

Liver-directed Diseases

Other Hereditary Diseases

Adeno-Associated Virus (AAV) Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno-Associated Virus (AAV) Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adeno-Associated Virus (AAV) Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno-Associated Virus (AAV) Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Adeno-Associated Virus (AAV) Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adeno-Associated Virus (AAV) Gene Therapy industry.

Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Gene Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adeno-Associated Virus (AAV) Gene Therapyrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Luxturna Table 3. Key Players of Zolgensma Table 4. Key Players of Others Table 4. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Central Nervous System Diseases Table 6. Key Players of Ocular Diseases Table 7. Key Players of Liver-directed Diseases Table 8. Key Players of Other Hereditary Diseases Table 9. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2021-2026) Table 12. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2027-2032) Table 14. Adeno-Associated Virus (AAV) Gene Therapy Industry Trends Table 15. Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers Table 16. Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges Table 17. Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints Table 18. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Company (2021-2026) Table 20. Global Adeno-Associated Virus (AAV) Gene Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Adeno-Associated Virus (AAV) Gene Therapy Key Company Head Office and Area Served Table 22. Global Adeno-Associated Virus (AAV) Gene Therapy Company, Product Type & Application Table 23. Global Adeno-Associated Virus (AAV) Gene Therapy Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Adeno-Associated Virus (AAV) Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2021-2026) Table 30. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2027-2032) Table 31. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021-2026) Table 35. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2027-2032) Table 36. AGC Biologics Company Information Table 37. AGC Biologics Business Overview Table 38. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 40. AGC Biologics Recent Development Table 41. StrideBio Company Information Table 42. StrideBio Business Overview Table 43. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 45. StrideBio Recent Development Table 46. SIRION Biotech Company Information Table 47. SIRION Biotech Business Overview Table 48. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 50. SIRION Biotech Recent Development Table 51. Neurophth Biotechnology Company Information Table 52. Neurophth Biotechnology Business Overview Table 53. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 55. Neurophth Biotechnology Recent Development Table 56. Belief BioMed Company Information Table 57. Belief BioMed Business Overview Table 58. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 60. Belief BioMed Recent Development Table 61. BiBo Biopharma Engineering Co., LTD. Company Information Table 62. BiBo Biopharma Engineering Co., LTD. Business Overview Table 63. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 65. BiBo Biopharma Engineering Co., LTD. Recent Development Table 66. Beihai Kangcheng Company Information Table 67. Beihai Kangcheng Business Overview Table 68. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 70. Beihai Kangcheng Recent Development Table 71. PackGene Biotech Company Information Table 72. PackGene Biotech Business Overview Table 73. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 75. PackGene Biotech Recent Development Table 76. Sarepta Therapeutics Company Information Table 77. Sarepta Therapeutics Business Overview Table 78. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 80. Sarepta Therapeutics Recent Development Table 81. Carbon BioSciences Company Information Table 82. Carbon BioSciences Business Overview Table 83. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 85. Carbon BioSciences Recent Development Table 86. Kelonia Therapeutics Company Information Table 87. Kelonia Therapeutics Business Overview Table 88. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 90. Kelonia Therapeutics Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 95. Roche Recent Development Table 96. Remedium Bio Company Information Table 97. Remedium Bio Business Overview Table 98. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 100. Remedium Bio Recent Development Table 101. Creative Biolabs Company Information Table 102. Creative Biolabs Business Overview Table 103. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 105. Creative Biolabs Recent Development Table 106. Affinia Therapeutics Company Information Table 107. Affinia Therapeutics Business Overview Table 108. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 110. Affinia Therapeutics Recent Development Table 111. Spark Therapeutics Company Information Table 112. Spark Therapeutics Business Overview Table 113. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 115. Spark Therapeutics Recent Development Table 116. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 117. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 118. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 119. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 120. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) Table 122. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032) Table 123. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 124. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 125. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 126. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 127. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) Table 129. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032) Table 130. China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 131. China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 132. China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 133. China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 134. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 135. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 136. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 137. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 138. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) Table 140. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032) Table 141. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 142. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 143. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 144. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 145. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) Table 147. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Adeno-Associated Virus (AAV) Gene Therapy Product Image Figure 2. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type: 2025 VS 2032 Figure 4. Luxturna Image Figure 5. Zolgensma Image Figure 6. Others Image Figure 7. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application: 2025 VS 2032 Figure 9. Central Nervous System Diseases Image Figure 10. Ocular Diseases Image Figure 11. Liver-directed Diseases Image Figure 12. Other Hereditary Diseases Image Figure 13. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 15. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Type (2021-2032) Figure 22. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Application (2021-2032) Figure 24. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 25. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032) Figure 26. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032) Figure 27. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 28. United States Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 29. Canada Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 31. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 32. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032) Figure 33. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032) Figure 34. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 35. Germany Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 36. France Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 38. Italy Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 39. Russia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 41. China Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 42. China Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032) Figure 43. China Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032) Figure 44. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 45. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032) Figure 46. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032) Figure 47. Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 48. Japan Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 52. India Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 53. Australia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 58. Brazil Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 63. UAE Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 65. Chile Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Luxturna
  • Zolgensma
  • Others
Applications
  • Central Nervous System Diseases
  • Ocular Diseases
  • Liver-directed Diseases
  • Other Hereditary Diseases
Companies covered
  • AGC Biologics
  • StrideBio
  • SIRION Biotech
  • Neurophth Biotechnology
  • Belief BioMed
  • BiBo Biopharma Engineering Co., LTD.
  • Beihai Kangcheng
  • PackGene Biotech
  • Sarepta Therapeutics
  • Carbon BioSciences
  • Kelonia Therapeutics
  • Roche
  • Remedium Bio
  • Creative Biolabs
  • Affinia Therapeutics
  • Spark Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Luxturna
  5. 1.2.3 Zolgensma
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Central Nervous System Diseases
  10. 1.3.3 Ocular Diseases
  11. 1.3.4 Liver-directed Diseases
  12. 1.3.5 Other Hereditary Diseases
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Adeno-Associated Virus (AAV) Gene Therapy Growth Trends by Region
  15. 1.5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026)
  17. 1.5.3 Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Dynamics
  1. 2.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Trends
  2. 2.2 Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers
  3. 2.3 Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Company (2021-2026)
  2. 3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Adeno-Associated Virus (AAV) Gene Therapy Key Company Head office and Area Served
  4. 3.4 Global Adeno-Associated Virus (AAV) Gene Therapy Company, Product Type & Application
  5. 3.5 Global Adeno-Associated Virus (AAV) Gene Therapy Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Adeno-Associated Virus (AAV) Gene Therapy Tier 1, Tier 2, and Tier 3
4 Adeno-Associated Virus (AAV) Gene Therapy Market by Type
  1. 4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2032)
  3. 4.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032)
5 Adeno-Associated Virus (AAV) Gene Therapy Market by Application
  1. 5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2032)
  3. 5.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 AGC Biologics
  2. 6.1.1 AGC Biologics Company Information
  3. 6.1.2 AGC Biologics Business Overview
  4. 6.1.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  6. 6.1.5 AGC Biologics Recent Developments
  7. 6.2 StrideBio
  8. 6.2.1 StrideBio Company Information
  9. 6.2.2 StrideBio Business Overview
  10. 6.2.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  12. 6.2.5 StrideBio Recent Developments
  13. 6.3 SIRION Biotech
  14. 6.3.1 SIRION Biotech Company Information
  15. 6.3.2 SIRION Biotech Business Overview
  16. 6.3.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  18. 6.3.5 SIRION Biotech Recent Developments
  19. 6.4 Neurophth Biotechnology
  20. 6.4.1 Neurophth Biotechnology Company Information
  21. 6.4.2 Neurophth Biotechnology Business Overview
  22. 6.4.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  24. 6.4.5 Neurophth Biotechnology Recent Developments
  25. 6.5 Belief BioMed
  26. 6.5.1 Belief BioMed Company Information
  27. 6.5.2 Belief BioMed Business Overview
  28. 6.5.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  30. 6.5.5 Belief BioMed Recent Developments
  31. 6.6 BiBo Biopharma Engineering Co., LTD.
  32. 6.6.1 BiBo Biopharma Engineering Co., LTD. Company Information
  33. 6.6.2 BiBo Biopharma Engineering Co., LTD. Business Overview
  34. 6.6.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  36. 6.6.5 BiBo Biopharma Engineering Co., LTD. Recent Developments
  37. 6.7 Beihai Kangcheng
  38. 6.7.1 Beihai Kangcheng Company Information
  39. 6.7.2 Beihai Kangcheng Business Overview
  40. 6.7.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  42. 6.7.5 Beihai Kangcheng Recent Developments
  43. 6.8 PackGene Biotech
  44. 6.8.1 PackGene Biotech Company Information
  45. 6.8.2 PackGene Biotech Business Overview
  46. 6.8.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  48. 6.8.5 PackGene Biotech Recent Developments
  49. 6.9 Sarepta Therapeutics
  50. 6.9.1 Sarepta Therapeutics Company Information
  51. 6.9.2 Sarepta Therapeutics Business Overview
  52. 6.9.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  54. 6.9.5 Sarepta Therapeutics Recent Developments
  55. 6.10 Carbon BioSciences
  56. 6.10.1 Carbon BioSciences Company Information
  57. 6.10.2 Carbon BioSciences Business Overview
  58. 6.10.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  60. 6.10.5 Carbon BioSciences Recent Developments
  61. 6.11 Kelonia Therapeutics
  62. 6.11.1 Kelonia Therapeutics Company Information
  63. 6.11.2 Kelonia Therapeutics Business Overview
  64. 6.11.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  66. 6.11.5 Kelonia Therapeutics Recent Developments
  67. 6.12 Roche
  68. 6.12.1 Roche Company Information
  69. 6.12.2 Roche Business Overview
  70. 6.12.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  72. 6.12.5 Roche Recent Developments
  73. 6.13 Remedium Bio
  74. 6.13.1 Remedium Bio Company Information
  75. 6.13.2 Remedium Bio Business Overview
  76. 6.13.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  78. 6.13.5 Remedium Bio Recent Developments
  79. 6.14 Creative Biolabs
  80. 6.14.1 Creative Biolabs Company Information
  81. 6.14.2 Creative Biolabs Business Overview
  82. 6.14.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  84. 6.14.5 Creative Biolabs Recent Developments
  85. 6.15 Affinia Therapeutics
  86. 6.15.1 Affinia Therapeutics Company Information
  87. 6.15.2 Affinia Therapeutics Business Overview
  88. 6.15.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  90. 6.15.5 Affinia Therapeutics Recent Developments
  91. 6.16 Spark Therapeutics
  92. 6.16.1 Spark Therapeutics Company Information
  93. 6.16.2 Spark Therapeutics Business Overview
  94. 6.16.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  96. 6.16.5 Spark Therapeutics Recent Developments
7 North America
  1. 7.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  2. 7.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  3. 7.2.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026)
  4. 7.2.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032)
  5. 7.2.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032)
  6. 7.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 7.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026)
  8. 7.3.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032)
  9. 7.3.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032)
  10. 7.4 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
  11. 7.4.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  13. 7.4.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
  14. 7.4.4 North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  2. 8.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  3. 8.2.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026)
  4. 8.2.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032)
  5. 8.2.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032)
  6. 8.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 8.3.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026)
  8. 8.3.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032)
  9. 8.3.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032)
  10. 8.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
  11. 8.4.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  13. 8.4.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
  14. 8.4.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  2. 9.2 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  3. 9.2.1 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026)
  4. 9.2.2 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032)
  5. 9.2.3 China Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032)
  6. 9.3 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 9.3.1 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026)
  8. 9.3.2 China Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032)
  9. 9.3.3 China Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  2. 10.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  3. 10.2.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026)
  4. 10.2.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032)
  5. 10.2.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032)
  6. 10.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 10.3.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026)
  8. 10.3.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032)
  9. 10.3.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032)
  10. 10.4 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
  11. 10.4.1 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  13. 10.4.3 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
  14. 10.4.4 Asia Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst